MADRID — New data from two randomized trials suggest that dual antiplatelet therapy (DAPT) should be significantly shortened or not used at all after coronary artery bypass surgery (CABG). Researchers ...
A small Chinese trial compared the effects of three oral antispastic medications for 24 weeks post-coronary artery bypass grafting (CABG) in relation to spasm-induced radial artery graft failure.
MADRID, Spain—Adding ticagrelor on top of aspirin alone for 1 year does not lower the incidence of death, MI, stroke, or repeat revascularization in ACS patients who undergo CABG surgery, according to ...
Hosted on MSN
De-escalation of dual antiplatelet therapy provides benefits in patients after coronary artery bypass grafting
Compared with dual antiplatelet therapy (DAPT), a de-escalated DAPT strategy resulted in similar graft occlusion rates and reduced clinically relevant bleeding in patients who underwent coronary ...
MADRID, Spain—Adding evolocumab (Repatha; Amgen) to statin therapy does not lower the risk of saphenous vein graft (SVG) failure among patients who undergo coronary artery bypass surgery, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results